BIT (ASX) $10 Billion Deal

Originally posted by eob18 ↑

What are the good projects in Australia's "Global Biotechnology Capital"?
2020-04-20 11:36:33 Source: Internet Classification: Related Articles
Over the past five years, investment and financing activities in China's medical and health industry have become increasingly frequent.
IT orange data shows that from January to November 2016, there were 293 projects received, with a total investment of 36 billion yuan, of which 50% of the financing of biotechnology projects were in the hundreds of millions of dollars.
As valuations of domestic biotechnology companies have increased, capital has gradually shifted exports to places such as the United States and Israel overseas. In Australia, which ranks fifth in the world in biotechnology, few Chinese companies are deployed.
In fact, Australia has a very superior ecological environment for the development and transformation of innovative biotechnology.
In terms of government investment, tax relief, clinical trial approval mechanism and intellectual property protection, the Australian government has given strong support to biotechnology innovation. About 1,000 new clinical trials of medicines and medical equipment are conducted in Australia every year.
In terms of talents, Australia has two of the world ’s top medical schools-the University of Melbourne and Monash University, more than 50 of the world ’s top medical research institutes, as well as ACABS (Australian Chinese Biomedical Association), ACASE (Australian Chinese Scientist Entrepreneur Association), CAPS (Australia China Doctoral Salon) and other industry associations closely related to China.
On the industrial level, there are more than 500 biotechnology companies in Australia, of which 35 are listed companies with a market value of more than 13 billion Australian dollars.
On March 27, at the China-Australia Biotechnology Investment Conference co-hosted by AusBiotech (Australian Biomedical Association), MTP Connect, China Bluesky and Pfarrell, 14 Australian companies (including 5 listed companies and 7 biotechnology companies) Landed in China with original patents and technologies. As a media support, Shell Society visited the site in person and brought readers an outline of Australia's biotechnology investment.
Biotechnology
Biotron
Biotron Limited (ASX: BIT) is a listed biotechnology company based in Sydney, Australia, which develops new drugs for serious viral diseases. The company is developing and commercializing a new small molecule drug that treats multiple viral diseases. Scientists have discovered the virus protein of Viroporin in many viruses, and it is essential for the pathogenicity of the virus. The core technology of Biotron is to target attacks called viroporins. The company has developed a key library of viroporin inhibitors and screening assays for key viral targets.
The company's main drug is BIT225, which focuses on HIV-1 and hepatitis C virus (HCV), and is currently in clinical phase II.
In addition to its clinical development plan for BIT225, Biotron also has drug development plans for other viruses, including dengue and respiratory viruses, Ebola and Zika viruses.
Biotron is seeking a partnership to further the clinical development of its projects, and is also collaborating on the commercialization of antiviral assets.

https://www.hotbak.net/key/澳...哪些好项目.html

Expand

What's even more disappointing with this article is that there is no reference to CoVid19 program!!!

No.	Vol.	Price($)
3	299538	2.7¢

No.

Vol.

Price($)

299538

2.7¢

Price($)	Vol.	No.
2.9¢	361626	2

Price($)

Vol.

No.

2.9¢

361626

No.	Vol.	Price($)
3	299538	0.027
7	539518	0.026
5	268646	0.025
2	249000	0.024
2	430000	0.023

No.

Vol.

Price($)

299538

0.027

539518

0.026

268646

0.025

249000

0.024

430000

0.023

Price($)	Vol.	No.
0.029	361626	2
0.030	60000	2
0.031	80000	3
0.032	500000	1
0.033	98650	1

Price($)

Vol.

No.

0.029

361626

0.030

60000

0.031

80000

0.032

500000

0.033

98650

(20min delay)
Last 2.8¢		Change 0.000(0.00%)		Mkt cap ! $24.36M

Open	High	Low	Value	Volume
2.7¢	2.8¢	2.7¢	$140	5.161K

$10 Billion Deal, page-6113

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Adairs MD and CEO steps down after 17 years in company management

China's Xingye snags 19.99% stake in Far East Gold, eyeing latter's Indonesian gold play

Delorean unlocks $30M through Tanarra finance facility for bioenergy projects

ACCC says no issue with TPG Telecom and Optus Mobile sharing regional networks; spectrum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

$10 Billion Deal, page-6113

Top Stories

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Adairs MD and CEO steps down after 17 years in company management

China's Xingye snags 19.99% stake in Far East Gold, eyeing latter's Indonesian gold play

Delorean unlocks $30M through Tanarra finance facility for bioenergy projects

ACCC says no issue with TPG Telecom and Optus Mobile sharing regional networks; spectrum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News